ReviewCurrent allergy and asthma reports2011
Guillain-barré syndrome: modern theories of etiology.
Review in Current allergy and asthma reports, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 4 syntheses or guidelines pooled it, 63 citations in OpenAlex.
- Arbovirus-Associated Guillain-Barré Syndrome: A Systematic Review and Meta-Analysis of Clinical Characteristics, Subtypes, and Vaccine Associations.Immunity, inflammation and disease · 2026Pooled it
- Cyclophosphamide in the Treatment of Systemic Lupus Erythematosus-related Guillain-Barré Syndrome: A Systematic Review of Case Reports.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2023Pooled it
- Guillain Barre Syndrome as a Complication of COVID-19: A Systematic Review.The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques · 2022Pooled it
- Guillain-Barré syndrome and influenza vaccines: current evidence.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2019Pooled it
- Clinical Criteria to Guide Antineuronal Antibody Testing for People With Early and Persistent Psychosis Attending Mental Health Services.Biological psychiatry global open science · 2026Article
- Blood DNA virome associates with autoimmune diseases and COVID-19.Nature genetics · 2025Article
- Article
- Incidence of Guillain-Barré syndrome in the world between 1985 and 2020: A systematic review.Global epidemiology · 2023Review
- Article
- COVID-19 as a trigger of Guillain-Barré syndrome: A review of the molecular mechanism.Immunity, inflammation and disease · 2023Review
- Identification of factors affecting outcomes in patients with Guillain Barre syndrome.Medicine and pharmacy reports · 2022Article
- Sex differences in Guillain Barré syndrome, chronic inflammatory demyelinating polyradiculoneuropathy and experimental autoimmune neuritis.Frontiers in immunology · 2022Review
- Acute Pericarditis as the Primary Presentation of COVID-19 Infection followed by Guillain-Barre Syndrome in a Healthy Young Man: A Case Report.The open respiratory medicine journal · 2022Article
- Concomitant Guillain-Barre syndrome with COVID-19: a case report.BMC neurology · 2021Article
- Vaccines and the risk of Guillain-Barré syndrome.European journal of epidemiology · 2020Article
- Review
- Isolated adrenocorticotropic hormone (ACTH) deficiency and Guillain-Barré syndrome occurring in a patient treated with nivolumab.BMJ case reports · 2019Article
- Reactivation of Chronic Hepatitis C as a Potential Trigger for Guillain-Barré Syndrome.Cureus · 2019Article
- Incidence study of Guillain-Barré syndrome in the province of Ferrara, Northern Italy, between 2003 and 2017. A 40-year follow-up.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2019Article
- Comment on: Zika virus and Guillain-Barré syndrome in Bangladesh.Annals of clinical and translational neurology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Guillain-Barré syndrome (GBS) is a classic failure of the immune system with a life-threatening attack upon a critical self-component. The active phase of the disease is short, concordant with the latency of a primary adaptive immune response. Triggers for GBS include infection and (rarely) vaccination; cross-reactivity between infectious and neural epitopes has been well demonstrated, particularly for Campylobacter jejuni and motor axonal forms of GBS in which non-protein gangliosides are antigenic. Most people are probably exposed to a GBS trigger, but only rarely does the disease develop. We propose that GBS illustrates competing determinants of the immune system's decision about whether to mount a response, and that in unlucky affected individuals, co-presentation of cross-reactive antigens with danger signals activating pattern-recognition receptors overcomes normal self-recognition such that a primary response is initiated that attacks the nerve. Then, in most cases of GBS, the response rapidly turns off, and second attacks rarely occur. This suggests active restoration of tolerance, and specific privileged site attributes of nerve and declining danger signals as the trigger wanes may contribute to this restoration. Standard immunosuppression has not been effective in GBS. We suggest this is because immune tolerance is already being restored by the time such therapies are initiated. This in turn suggests that improvements in GBS outcomes are likely to come from better protection of the nerve cells under attack while normal resumption of tolerance is permitted to proceed rather than exploring more aggressive immunosuppressive approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.